P E Keck

Summary

Affiliation: University of Cincinnati
Country: USA

Publications

  1. ncbi Definition, evaluation, and management of treatment refractory mania
    P E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, P O Box 670559, Cincinnati, OH 45267 0559, USA
    Psychopharmacol Bull 35:130-48. 2001
  2. ncbi A pilot study of rapid lithium administration in the treatment of acute mania
    P E Keck
    Biological Psychiatry Program, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    Bipolar Disord 3:68-72. 2001
  3. ncbi Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267 0559, USA
    J Clin Psychiatry 63:3-11. 2002
  4. ncbi What makes a drug a primary mood stabilizer?
    P E Keck
    Biological Psychiatry Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    Mol Psychiatry 7:S8-14. 2002
  5. ncbi Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, OH 45627 0559, USA
    Am J Psychiatry 160:741-8. 2003
  6. ncbi Redefining mood stabilization
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    J Affect Disord 73:163-9. 2003
  7. ncbi Comparison of patients with early-, typical-, and late-onset affective psychosis
    K W Sax
    Department of Psychiatry, University of Cincinnati College of Medicine, OH, USA
    Am J Psychiatry 154:1299-301. 1997
  8. ncbi A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group
    C L Bowden
    Department of Psychiatry, University of Texas Health Science Center at San Antonio, 78284 7792, USA
    Arch Gen Psychiatry 57:481-9. 2000
  9. doi Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study
    P E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, and Linder Center of HOPE, Mason, Ohio 45267, USA
    J Affect Disord 112:36-49. 2009
  10. ncbi Attentional improvement following quetiapine fumarate treatment in schizophrenia
    K W Sax
    Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    Schizophr Res 33:151-5. 1998

Collaborators

Detail Information

Publications88

  1. ncbi Definition, evaluation, and management of treatment refractory mania
    P E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, P O Box 670559, Cincinnati, OH 45267 0559, USA
    Psychopharmacol Bull 35:130-48. 2001
    ..Field testing of treatment algorithms and systematic collection of data from naturalistic treatment studies should provide much-needed data regarding the efficacy of antimanic agents in treatment refractory mania...
  2. ncbi A pilot study of rapid lithium administration in the treatment of acute mania
    P E Keck
    Biological Psychiatry Program, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    Bipolar Disord 3:68-72. 2001
    ..A secondary aim was to provide preliminary data regarding the efficacy of this strategy in ameliorating manic, depressive, and psychotic symptoms...
  3. ncbi Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267 0559, USA
    J Clin Psychiatry 63:3-11. 2002
    ..We reviewed the clinical pharmacodynamics and pharmacokinetics of these agents to provide a summary of these properties relevant to clinical practice...
  4. ncbi What makes a drug a primary mood stabilizer?
    P E Keck
    Biological Psychiatry Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    Mol Psychiatry 7:S8-14. 2002
    ..In addition, potential pharmacological mechanisms underlying mood-stabilizing effects of established compounds are reviewed...
  5. ncbi Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, OH 45627 0559, USA
    Am J Psychiatry 160:741-8. 2003
    ..The study evaluated the efficacy and tolerability of ziprasidone, compared with placebo, in the treatment of adult patients with acute bipolar mania...
  6. ncbi Redefining mood stabilization
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    J Affect Disord 73:163-9. 2003
    ..No available agent meets the criteria for a comprehensive mood-stabilizer, although lithium comes the closest...
  7. ncbi Comparison of patients with early-, typical-, and late-onset affective psychosis
    K W Sax
    Department of Psychiatry, University of Cincinnati College of Medicine, OH, USA
    Am J Psychiatry 154:1299-301. 1997
    ..The authors compared the clinical characteristics and family history of patients with early-onset (before age 18), typical-onset (at 20-25 years), and late-onset (after age 35) affective psychosis at the time of first hospitalization...
  8. ncbi A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group
    C L Bowden
    Department of Psychiatry, University of Texas Health Science Center at San Antonio, 78284 7792, USA
    Arch Gen Psychiatry 57:481-9. 2000
    ..This study compared the efficacy of divalproex, lithium, and placebo as prophylactic therapy...
  9. doi Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study
    P E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, and Linder Center of HOPE, Mason, Ohio 45267, USA
    J Affect Disord 112:36-49. 2009
    ..To evaluate the efficacy and safety of aripiprazole as acute and maintenance of effect monotherapy for acute bipolar mania...
  10. ncbi Attentional improvement following quetiapine fumarate treatment in schizophrenia
    K W Sax
    Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    Schizophr Res 33:151-5. 1998
    ..These results suggest that quetiapine produces a significant improvement in attentional functioning in patients with schizophrenia...
  11. ncbi Bipolar disorder
    P E Keck
    Department of Psychiatry, Biological Psychiatry Program, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Med Clin North Am 85:645-61, ix. 2001
    ..Fortunately, several medications are now available to treat the acute mood episodes of bipolar disorder and to prevent further episodes with maintenance treatment...
  12. ncbi Linkage of a bipolar disorder susceptibility locus to human chromosome 13q32 in a new pedigree series
    S H Shaw
    Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA
    Mol Psychiatry 8:558-64. 2003
    ..These pedigrees provide additional evidence for at least one locus for BP disorder in 13q32, and are consistent with other reports of a possible genetic overlap between these disorders...
  13. ncbi Pharmacologic loading in the treatment of acute mania
    P E Keck
    Biological Psychiatry Program, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    Bipolar Disord 2:42-6. 2000
    ..Further double-blind, controlled studies with adequate sample sizes comparing loading strategies with more gradual titration schedules of candidate antimanic agents are needed...
  14. ncbi A placebo-controlled, crossover trial of granisetron in SRI-induced sexual dysfunction
    E B Nelson
    Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267-0559, USA
    J Clin Psychiatry 62:469-73. 2001
    ..A significant placebo response may be associated with the treatment of SRI-induced sexual dysfunction...
  15. ncbi Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder
    S L McElroy
    Stanley Foundation Bipolar Treatment Outcome Network, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    Am J Psychiatry 158:420-6. 2001
    ..Therefore, the authors assessed comorbid lifetime and current axis I disorders in 288 patients with bipolar disorder and the relationships of these comorbid disorders to selected demographic and historical illness variables...
  16. ncbi Ziprasidone: a new atypical antipsychotic
    P E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Ohio, USA
    Expert Opin Pharmacother 2:1033-42. 2001
    ..Unlike newer agents, it does not appear to be associated with weight gain in most patients...
  17. ncbi The effects of antecedent substance abuse on the development of first-episode psychotic mania
    S M Strakowski
    Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    J Psychiatr Res 30:59-68. 1996
    ..Additional prospective studies of patients with new onset bipolar disorder and antecedent substance abuse syndromes are needed to further clarify the complex relationships between substance abuse and bipolar disorder...
  18. ncbi Evaluation of bipolar disorder in inpatients with prelingual deafness
    N A Shapira
    Department of Psychiatry, University of Cincinnati College of Medicine, USA
    Am J Psychiatry 156:1267-9. 1999
    ..This study retrospectively examined the occurrence of bipolar disorder in patients with prelingual deafness who were hospitalized for a psychiatric disorder...
  19. ncbi Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies
    P E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267-0559, USA
    J Clin Psychopharmacol 21:27-35. 2001
    ..These results suggest that ziprasidone may have efficacy in the treatment of affective as well as psychotic symptoms of schizoaffective disorder, with a low side-effect burden...
  20. ncbi Frontosubcortical neuroanatomy and the continuous performance test in mania
    K W Sax
    Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    Am J Psychiatry 156:139-41. 1999
    ..The authors examined whether Continuous Performance Test scores correlate with frontosubcortical volumes in bipolar disorder...
  21. ncbi An open trial of olanzapine in the treatment of patients with psychotic depression
    E B Nelson
    Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267-0559, USA
    Ann Clin Psychiatry 13:147-51. 2001
    ..001). The results of this pilot study suggest that olanzapine may be an effective treatment for some patients with unipolar psychotic depression. However, these observations require replication in randomized, controlled trials...
  22. ncbi Antidepressant treatment of fibromyalgia. A meta-analysis and review
    L M Arnold
    Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    Psychosomatics 41:104-13. 2000
    ....
  23. ncbi Prevalence and description of psychotic features in bipolar mania
    E Dunayevich
    Clinical Psychobiology Program, Department of Psychiatry, University of Cincinnati, PO Box 670559, Cincinnati, OH 45267 0559, USA
    Curr Psychiatry Rep 2:286-90. 2000
    ..Careful assessment of prior psychiatric history, family history, and treatment response can aid in the differentiation of affective disorders with psychotic features from psychotic disorders...
  24. ncbi Cerebrospinal fluid and plasma beta-endorphin in combat veterans with post-traumatic stress disorder
    D G Baker
    Psychiatry Service, Cincinnati Veterans Affairs Medical Center, OH 15220, USA
    Psychoneuroendocrinology 22:517-29. 1997
    ..Poor correlation between CSF and plasma ir beta END limits use of plasma measures to assess CNS opioid activity...
  25. ncbi Failure of glucagon-like peptide-1 to induce panic attacks or anxiety in patients with panic disorder
    J R Strawn
    Cincinnati Veterans Affairs Medical Center, Research Service, Cincinnati, OH 45220, USA
    J Psychiatr Res 42:787-9. 2008
    ..These data suggest that in humans, intraveneously administered GLP-1 does not appear to have anxiogenic or panicogenic properties, even in patients at highest risk for such reactions...
  26. ncbi Residual catatonic state following neuroleptic malignant syndrome
    S N Caroff
    Department of Psychiatry, University of Pennsylvania School of Medicine, and the Department of Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 20:257-9. 2000
    ..Although patients may improve gradually with supportive care or pharmacotherapy, ECT can often be highly effective in treating the residual catatonic state that follows NMS...
  27. ncbi CSF norepinephrine concentrations in posttraumatic stress disorder
    T D Geracioti
    Mental Health Service, Veterans Affairs Medical Center, 3200 Vine St, Cincinnati, OH 45220, USA
    Am J Psychiatry 158:1227-30. 2001
    ..The goal of this study was to determine serial CSF norepinephrine levels in patients with PTSD...
  28. ncbi Health values of patients with bipolar disorder
    J Tsevat
    Section of Outcomes Research, Division of General Internal Medicine, Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio, USA
    Qual Life Res 9:579-86. 2000
    ..Despite a growing number of studies of patients' health values (utilities), little is known about health values of patients with mental illness, particularly bipolar (manic-depressive) disorder...
  29. ncbi Evidence that a single nucleotide polymorphism in the promoter of the G protein receptor kinase 3 gene is associated with bipolar disorder
    T B Barrett
    Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093 0603, USA
    Mol Psychiatry 8:546-57. 2003
    ..7 (chi(2)=9.6, one-sided P value=0.0019). Altogether, these data support the hypothesis that a dysregulation in GRK3 expression alters signaling desensitization, and thereby predisposes to the development of BPD...
  30. ncbi Comparison of obese men and women with binge eating disorder seeking weight management
    A I Guerdjikova
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    Eat Weight Disord 12:e19-23. 2007
    ....
  31. ncbi Lithium augmentation of topiramate for bipolar disorder with comorbid binge eating disorder and obesity
    Renu Kotwal
    Department of Psychiatry, Psychopharmacology Research Program, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    Hum Psychopharmacol 21:425-31. 2006
    ..To evaluate the effectiveness of lithium augmentation of topiramate on mood symptoms, binge eating behavior, and body weight in obese bipolar patients with binge eating disorder (BED) seeking weight management...
  32. ncbi A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression
    Eileen B Brown
    Lilly Research Laboratories, Indianapolis, IN, USA
    J Clin Psychiatry 67:1025-33. 2006
    ..Determine the efficacy and tolerability of olanzapine/fluoxetine combination (OFC) for treatment of acute bipolar I depression compared with lamotrigine...
  33. ncbi A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression
    Sara A Corya
    Lilly Research Laboratories, Indianapolis, Ind, USA
    J Clin Psychiatry 67:798-806. 2006
    ..The present analyses examined the efficacy and safety of longer term treatment with olanzapine-fluoxetine combination or olanzapine monotherapy in a 6-month open-label extension study...
  34. ncbi Early bicarbonate loading and dantroline for ziprasidone/haloperidol-induced neuroleptic malignant syndrome
    Jeffrey R Strawn
    J Clin Psychiatry 67:677. 2006
  35. ncbi Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials
    Roy H Perlis
    Bipolar Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 67:509-16. 2006
    ..However, there are no published comparisons of individual atypical antipsychotics for mania...
  36. ncbi Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials
    Richard H Weisler
    Department of Psychiatry and Behavioral Science, Duke University, Raleigh, North Carolina 27609, USA
    CNS Drugs 20:219-31. 2006
    ..By pooling data from these two trials, a more highly powered analysis of the efficacy and safety of CBZ-ERC in bipolar I disorder could be conducted...
  37. ncbi Treatment costs related to bipolar disorder and comorbid conditions among Medicaid patients with bipolar disorder
    Jeff J Guo
    Division of Pharmacy Practice and Administrative Sciences, College of Pharmacy and the Institute for the Study of Health, University of Cincinnati Academic Health Center, 3225 Eden Avenue, Cincinnati, OH 45267 0004, USA
    Psychiatr Serv 58:1073-8. 2007
    ..This study assessed costs among patients with bipolar disorder for treatment related to bipolar disorder and to comorbid conditions. Risk factors associated with costs were also assessed...
  38. ncbi Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers
    Gabriele S Leverich
    Biological Psychiatry Branch, National Institutes of Mental Health, Bldg 10 Room 3S239, 10 Center Drive, MSC 1272, Bethesda, MD 20892 1272, USA
    Am J Psychiatry 163:232-9. 2006
    ..The authors examined the comparative risks of switches in mood polarity into hypomania or mania during acute and continuation trials of adjunctive antidepressant treatment of bipolar depression...
  39. ncbi A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression
    Joseph R Calabrese
    University Hospitals of Cleveland and Case University School of Medicine, 11400 Euclid Ave, Suite 200, Cleveland, OH 44106, USA
    Am J Psychiatry 162:1351-60. 2005
    ..There is a major unmet need for effective options in the treatment of bipolar depression...
  40. ncbi Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial
    Steven G Potkin
    Neuropsychiatric Center, University of California Irvine, 101 City Drive South, Bldg 3, Orange, CA 92868 3298, USA
    J Clin Psychopharmacol 25:301-10. 2005
    ..In an earlier 21-day, placebo-controlled trial, ziprasidone was efficacious in improving symptoms of mania and was well tolerated. To confirm these results, a similarly designed 21-day trial was conducted...
  41. ncbi The Texas implementation of medication algorithms update for treatment of bipolar I disorder
    Roy H Perlis
    Bipolar Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Mass 02114, USA
    J Clin Psychiatry 66:818-20. 2005
  42. ncbi Phenomenology associated with age at onset in patients with bipolar disorder at their first psychiatric hospitalization
    Nick C Patel
    College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267 0004, USA
    Bipolar Disord 8:91-4. 2006
    ..To compare the clinical presentation of patients with early-onset (age <18 years) and typical-onset (age 20-30 years) bipolar disorder at the time of first hospitalization...
  43. ncbi Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenon
    Trisha Suppes
    Bipolar Disorder Research Program, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas 75390 9121, USA
    Arch Gen Psychiatry 62:1089-96. 2005
    ..The prevalence of depressive symptoms co-occurring with hypomanic symptoms has not been quantified. Whether there is a greater likelihood for women to experience mixed symptoms has not been resolved...
  44. ncbi Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study
    Lori L Altshuler
    Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, CA, USA
    J Clin Psychiatry 67:1551-60. 2006
    ..Research examining this relationship in persons with bipolar disorder is rare. This study sought to evaluate the association between subsyndromal depressive symptoms and role functioning in subjects with bipolar disorder...
  45. ncbi Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants
    Lori L Altshuler
    Dept of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, 300 UCLA Medical Plaza, Suite 1544, Box 957057, Los Angeles, CA 90095 7057
    Am J Psychiatry 163:313-5. 2006
    ..The authors compared the switch rate into hypomania/mania in depressed patients treated with second-generation antidepressants who had either bipolar I or bipolar II disorder...
  46. ncbi Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    J Clin Psychiatry 68:1480-91. 2007
    ..Efficacy and tolerability of aripiprazole for relapse prevention in bipolar I disorder was, therefore, evaluated for 100 weeks...
  47. ncbi Quetiapine for the continuation treatment of bipolar depression: naturalistic prospective case series from the Stanley Bipolar Treatment Network
    Trisha Suppes
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9121, USA
    Int Clin Psychopharmacol 22:376-81. 2007
    ..No between-group differences in improvement were found. Adjunctive quetiapine may be useful as continuation treatment in bipolar populations with both pure depressive and cycling symptoms. Further controlled studies are warranted...
  48. ncbi A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: prospective studies are needed
    Drew H Barzman
    Children s Hospital Medical Center, Division of Child and Adolescent Psychiatry, Cincinnati, Ohio 45229 3039, USA
    J Child Adolesc Psychopharmacol 17:503-9. 2007
    ..Our secondary objective was to examine demographic and clinical factors associated with treatment response...
  49. ncbi A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression
    Mark A Frye
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, USA
    Am J Psychiatry 164:1242-9. 2007
    ..This study was conducted to evaluate the efficacy and safety of adjunctive modafinil in bipolar depression, which is often characterized by excessive sleepiness and fatigue...
  50. ncbi Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial
    Susan L McElroy
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    J Clin Psychiatry 68:390-8. 2007
    ..Binge-eating disorder (BED) is associated with obesity. Atomoxetine is a highly selective norepinephrine reuptake inhibitor associated with weight loss. The purpose of this study was to evaluate atomoxetine in the treatment of BED...
  51. ncbi Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study
    John Cookson
    The Department of Psychiatry, Royal London Hospital, London, UK
    Int Clin Psychopharmacol 22:93-100. 2007
    ..2%, quetiapine 300 mg/day: 3.9, and placebo: 3.9%). In conclusion, quetiapine compared with placebo significantly reduces time to response and remission compared with placebo, and has a favorable number needed to treat...
  52. ncbi Alcoholism and anxiety in bipolar illness: differential lifetime anxiety comorbidity in bipolar I women with and without alcoholism
    Eric Levander
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
    J Affect Disord 101:211-7. 2007
    ..This study was undertaken to evaluate the prevalence rate of anxiety comorbidity in bipolar subjects with and without alcohol use disorders (AUD)...
  53. ncbi Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial
    Susan L McElroy
    Psychopharmacology Research Program, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
    J Affect Disord 101:275-81. 2007
    ..Increasing evidence indicates that some second-generation antipsychotics are efficacious in bipolar depression, but there are few data on this illness for the novel agent aripiprazole...
  54. ncbi Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial
    Susan L McElroy
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    J Clin Psychiatry 67:1897-906. 2006
    ..Binge eating disorder (BED) is associated with obesity. Zonisamide is a novel antiepileptic drug associated with weight loss. The purpose of this study was to evaluate zonisa-mide in the treatment of BED associated with obesity...
  55. ncbi New findings from the Bipolar Collaborative Network: clinical implications for therapeutics
    Robert M Post
    Penn State College of Medicine, Hershey, PA, USA
    Curr Psychiatry Rep 8:489-97. 2006
    ..Finally, in treatment of overweight and obesity, topiramate and sibutramine showed equal efficacy but poor tolerability, and zonisamide data showed that it may be useful for mood and weight loss...
  56. ncbi The prevalence of the metabolic syndrome in psychiatric inpatients with primary psychotic and mood disorders
    Richard A Bermudes
    Department of Psychiatry and Behavioral Sciences, UC Davis Medical Center, Sacramento, CA 95817 1419, USA
    Psychosomatics 47:491-7. 2006
    ....
  57. ncbi Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients
    Ralph W Kupka
    Altrecht Institute for Mental Health Care, Tolsteegsingel 2A, 3582 AC Utrecht, Netherlands
    Am J Psychiatry 162:1273-80. 2005
    ..To detect risk factors for rapid cycling in bipolar disorder, the authors compared characteristics of rapid-cycling and non-rapid-cycling patients both from a categorical and a dimensional perspective...
  58. ncbi Bipolar depression: a new role for atypical antipsychotics?
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    Bipolar Disord 7:34-40. 2005
    ..001 versus placebo). These initial findings suggest that atypical antipsychotics may prove to be important future treatments for patients with bipolar depression...
  59. ncbi Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial
    Dennis A Revicki
    Center for Health Outcomes Research, MEDTAP International, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    J Affect Disord 86:183-93. 2005
    ..The clinical, quality of life (QOL), and medical cost outcomes of treatment with divalproex were compared with lithium in patients with bipolar I disorder over 1 year...
  60. ncbi Atypical antipsychotics in the treatment of bipolar disorder
    Stephen M Strakowski
    Department of Psychiatry, University of Cincinnati College of Medicine, PO Box 670559, Cincinnati, OH 45267 0559, USA
    Expert Opin Pharmacother 4:751-60. 2003
    ..Atypical antipsychotics offer different side effect profiles than older antipsychotics, which may be of benefit for some patients. Consequently, atypical antipsychotics provide an important treatment option for bipolar patients...
  61. ncbi Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder
    Mark A Frye
    Department of Psychiatry and Biobehavioral Sciences, UCLA Bipolar Research Program, University of California Los Angeles School of Medicine, 300 UCLA Medical Plaza, Suite 1544, Los Angeles, CA 90095, USA
    Am J Psychiatry 160:883-9. 2003
    ..This study examined gender-specific relationships between alcoholism and bipolar illness, which have previously received little systematic study...
  62. ncbi Impact of bipolar disorder on a U.S. community sample
    Joseph R Calabrese
    Department of Psychiatry, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio 44106, USA
    J Clin Psychiatry 64:425-32. 2003
    ..Bipolar symptoms have been associated with significant functional impairment. We conducted a study to determine the psychosocial impact of bipolar disorder in a U.S. community sample...
  63. ncbi Advances in the pharmacologic treatment of bipolar depression
    Paul E Keck
    Division of Psychopharmacology Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    Biol Psychiatry 53:671-9. 2003
    ....
  64. ncbi Long-term therapy of bipolar illness
    Paul E Keck
    University of Cincinnati College of Medicine, USA
    J Fam Pract . 2003
  65. ncbi Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine and General Clinical Research Center, Mental Health Service Line, Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, USA
    Expert Opin Investig Drugs 12:655-62. 2003
    ..In addition, aripiprazole was not associated with significant weight gain or QTc prolongation in both acute and long-term treatment trials...
  66. ncbi Screening for bipolar disorder in the community
    Robert M A Hirschfeld
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, 77555 188, USA
    J Clin Psychiatry 64:53-9. 2003
    ..Our goal was to estimate the rate of positive screens for bipolar I and bipolar II disorders in the general population of the United States...
  67. ncbi Carbamazepine and valproate in the maintenance treatment of bipolar disorder
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267 0559, USA
    J Clin Psychiatry 63:13-7. 2002
    ..We reviewed the available data from randomized clinical trials of these agents in bipolar disorder to assess their efficacy and tolerability in the maintenance phase of illness management...
  68. ncbi Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment
    Cesar A Soutullo
    University of Cincinnati, Department of Psychiatry, Biological Psychiatry and Psychotic and Bipolar Disorders Research Programs, PO Box 670559, 231 Bethesda Avenue, Cincinnati, OH 45267 0559, USA
    J Affect Disord 70:323-7. 2002
    ..Childhood bipolarity (BP) and ADHD frequently co-occur, these children often receive stimulants...
  69. ncbi Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000
    Trisha Suppes
    Department of Psychiatry The University of Texas Southwestern Medical Center Dallas, 75390 9070, USA
    J Clin Psychiatry 63:288-99. 2002
    ....
  70. ncbi Correlates of overweight and obesity in 644 patients with bipolar disorder
    Susan L McElroy
    Stanley Foundation Bipolar Treatment Outcome Network, Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267 0559, USA
    J Clin Psychiatry 63:207-13. 2002
    ..Overweight and obesity are common clinical problems encountered in the treatment of bipolar disorder. We therefore assessed the prevalence and clinical correlates of overweight, obesity, and extreme obesity in 644 bipolar patients...
  71. ncbi The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders
    Stephen M Strakowski
    Bipolar and Psychotic Disorders Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267 0559, USA
    J Clin Psychopharmacol 22:201-5. 2002
    ..No serious adverse events were observed during quetiapine treatment. No clinically relevant alterations in quetiapine pharmacokinetics were observed after cimetidine coadministration in patients with psychotic disorders...
  72. ncbi A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia
    Lesley M Arnold
    Women s Health Research Program, Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0559, USA
    Am J Med 112:191-7. 2002
    ..To assess the efficacy of fluoxetine in the treatment of patients with fibromyalgia...
  73. ncbi Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network
    Gabriele S Leverich
    Stanley Foundation Bipolar Treatment Outcome Network, Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health, Biological Psychiatry Branch, Bethesda, MD 20892 1272, USA
    J Clin Psychiatry 64:506-15. 2003
    ..We investigated demographic and course-of-illness variables to better understand the incidence and potential clinical correlates of serious suicide attempts in 648 outpatients with bipolar disorder...
  74. ncbi Maintenance efficacy of divalproex in the prevention of bipolar depression
    Laszlo Gyulai
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neuropsychopharmacology 28:1374-82. 2003
    ....
  75. ncbi Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    J Clin Psychiatry 66:611-6. 2005
    ..These subanalyses compare treatment-emergent mania rates in bipolar I depressed patients treated with olanzapine, placebo, or olanzapine/fluoxetine combination...
  76. ncbi Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder
    Robert M Post
    Biological Psychiatry Branch, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Clin Psychiatry 66:370-4. 2005
    ..Given the effectiveness of a range of other anticonvulsants in bipolar disorder, we sought to evaluate levetiracetam in patients with treatment-resistant illness...
  77. ncbi Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial
    Richard H Weisler
    Department of Psychiatry and Behavioral Sciences, Duke University, 700 Spring Forest, Suite 125, Raleigh, NC 27609, USA
    J Clin Psychiatry 66:323-30. 2005
    ..In the present study, we further evaluated the efficacy and safety of monotherapy with beaded, extended-release carbamazepine capsules (ERC-CBZ) in patients with bipolar I disorder experiencing manic or mixed episodes...
  78. ncbi Family study of fibromyalgia and affective spectrum disorder
    James I Hudson
    Biological Psychiatry Laboratory, McLean Hospital Department of Psychiatry, Harvard Medical School, Belmont, MA 02478, USA
    Biol Psychiatry 56:884-91. 2004
    ..Two predictions of the ASD hypothesis were tested: ASD, taken as a single entity, aggregates in families; and fibromyalgia coaggregates with other forms of ASD in families...
  79. ncbi Defining and improving response to treatment in patients with bipolar disorder
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    J Clin Psychiatry 65:25-9. 2004
    ..Psychoeducation for patients and families and interpersonal psychotherapy also can help prolong remission...
  80. ncbi Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network
    Willem A Nolen
    Altrecht Institute for Mental Health Care, Utrecht, The Netherlands
    Am J Psychiatry 161:1447-54. 2004
    ..The purpose of the study was to examine potential correlates of outcome in patients treated for bipolar disorder...
  81. ncbi Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial
    Robert M A Hirschfeld
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, TX 77555, USA
    Am J Psychiatry 161:1057-65. 2004
    ..This study evaluated the efficacy and safety of risperidone monotherapy in the treatment of acute bipolar mania...
  82. ncbi Family study of fibromyalgia
    Lesley M Arnold
    University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    Arthritis Rheum 50:944-52. 2004
    ..To assess for familial aggregation of fibromyalgia (FM) and measures of tenderness and pain, and for familial coaggregation of FM and major mood disorder (major depressive disorder or bipolar disorder)...
  83. ncbi Ethnicity and diagnosis in patients with affective disorders
    Stephen M Strakowski
    Bipolar and Psychotic Disorders Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    J Clin Psychiatry 64:747-54. 2003
    ..Why this occurs is unknown. Extending prior work, the authors hypothesized that first-rank symptoms distract clinicians so that they fail to identify affective disorders in African Americans...
  84. ncbi Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    Compr Psychiatry 44:263-9. 2003
    ..The lack of observable prognostic impact may have been, in part, due to the relatively high morbidity and poor functional outcome of a substantial portion of the total cohort...
  85. ncbi Olanzapine versus placebo in acute mania: treatment responses in subgroups
    Ross J Baldessarini
    International Consortium for Bipolar Disorder Research, Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA, USA
    J Clin Psychopharmacol 23:370-6. 2003
    ..5-1.7, all P < 0.01). These well-powered comparisons of subgroups of interest indicate broad efficacy of olanzapine in the treatment of acute mania...
  86. ncbi Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up
    Lori Altshuler
    Stanley Bipolar Treatment Network, USA
    Am J Psychiatry 160:1252-62. 2003
    ..This study examined the effect of antidepressant discontinuation or continuation on depressive relapse risk among bipolar subjects successfully treated for an acute depressive episode...
  87. ncbi Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method
    Robert M Post
    Stanley Foundation Bipolar Network and Biological Psychiatry Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 12723, USA
    J Clin Psychiatry 64:680-90; quiz 738-9. 2003
    ..The detailed course and pattern of illness emerging despite comprehensive treatment with mood stabilizers and adjunctive agents have previously not been well delineated...
  88. ncbi National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders
    Dennis S Charney
    Division of Intramural Research Programs, National Institute of Mental Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Arch Gen Psychiatry 59:262-70. 2002
    ..Research is needed on the ethical conduct of studies to limit risks of medication-free intervals and facilitate poststudy treatment. Patients must fully understand the risks and lack of individualized treatment involved in research...